[§104. Repealed. Pub. L. 112–29, §3(d), Sept. 16, 2011, 125 Stat. 287]
Section, act July 19, 1952, ch. 950, 66 Stat. 798; Pub. L. 93–596, §1, Jan. 2, 1975, 88 Stat. 1949; Pub. L. 94–131, §6, Nov. 14, 1975, 89 Stat. 691; Pub. L. 98–622, title IV, §403(a), Nov. 8, 1984, 98 Stat. 3392; Pub. L. 103–182, title III, §331, Dec. 8, 1993, 107 Stat. 2113; Pub. L. 103–465, title V, §531(a), Dec. 8, 1994, 108 Stat. 4982; Pub. L. 106–113, div. B, §1000(a)(9) [title IV, §4732(a)(10)(A)], Nov. 29, 1999, 113 Stat. 1536, 1501A–582; Pub. L. 107–273, div. C, title III, §13206(b)(1)(B), Nov. 2, 2002, 116 Stat. 1906; Pub. L. 112–29, §20(j), Sept. 16, 2011, 125 Stat. 335, related to inventions made abroad.
Statutory Notes and Related Subsidiaries
Effective Date of Repeal
Repeal effective upon the expiration of the 18-month period beginning on Sept. 16, 2011, and applicable to certain applications for patent and any patents issuing thereon, see section 3(n) of Pub. L. 112–29, set out as an Effective Date of 2011 Amendment; Savings Provisions note under section 100 of this title.
Court Cases Citing 35 U.S.C. § 104 (As of 2023)
- Realtek Semiconductor Corporation v. Marvell Technology Group LTD et al (2005)
- Novo Nordisk A/S et al v. Caraco Pharmaceutical Laboratories, Limited (2010)
- Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center. v. White (2005)
- Abbott Diabetes Care Inc. et al v. Roche Diagnostics Corporation et al (2008)
- Therasense, Inc. v. Nova Biomedical Corporation (2008)